EU/3/14/1261

About

On 11 April 2014, orphan designation (EU/3/14/1261) was granted by the European Commission to Viridian Pharma Ltd, United Kingdom, for caffeine citrate for the prevention of bronchopulmonary dysplasia.

Key facts

Active substance
Caffeine citrate
Disease / condition
Prevention of bronchopulmonary dysplasia
Date of first decision
11/04/2014
Outcome
Positive
EU designation number
EU/3/14/1261

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Viridian Pharma Ltd
Yew Tree House, Hendrew Lane
Llandevaud, Newport
Gwen, NP18 2AB
United Kingdom
Tel. +44 (0)163 3400 335
Fax +44 (0)163 3400 335
E-mail: info@viridianpharma.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating